Senti Bioscience Financials
This page shows Senti Bioscience (SNTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Senti Bioscience has an operating margin of -312631.8%, meaning the company retains $-312632 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Senti Bioscience has elevated debt relative to equity (D/E of 8.16), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Senti Bioscience's current ratio of 1.67 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 29/100, which could limit financial flexibility.
While Senti Bioscience generated -$43.4M in operating cash flow, capex of $196K consumed most of it, leaving -$43.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Senti Bioscience generates a -1099.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -205.8% the prior year.
Senti Bioscience passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Senti Bioscience generates $0.71 in operating cash flow (-$43.4M OCF vs -$61.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Senti Bioscience generated $22K in revenue in fiscal year 2025.
Senti Bioscience's EBITDA was -$65.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.9% from the prior year.
Senti Bioscience reported -$61.4M in net income in fiscal year 2025. This represents a decrease of 16.4% from the prior year.
Senti Bioscience earned $-2.73 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.3% from the prior year.
Cash & Balance Sheet
Senti Bioscience generated -$43.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 5.4% from the prior year.
Senti Bioscience held $16.4M in cash against $0 in long-term debt as of fiscal year 2025.
Senti Bioscience had 31M shares outstanding in fiscal year 2025. This represents an increase of 544.9% from the prior year.
Margins & Returns
Senti Bioscience's operating margin was -312631.8% in fiscal year 2025, reflecting core business profitability.
Senti Bioscience's net profit margin was -279263.6% in fiscal year 2025, showing the share of revenue converted to profit.
Senti Bioscience's ROE was -1099.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 893.5 percentage points from the prior year.
Capital Allocation
Senti Bioscience invested $12.9M in research and development in fiscal year 2025. This represents a decrease of 62.4% from the prior year.
Senti Bioscience invested $196K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 653.8% from the prior year.
SNTI Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $10.5M+4.9% | $10.0M+8.1% | $9.3M | N/A | $8.7M-5.4% | $9.2M+4.2% | $8.8M-3.8% | $9.1M |
| SG&A Expenses | $6.4M-5.0% | $6.8M-4.9% | $7.1M | N/A | $6.6M+56.0% | $4.2M-44.1% | $7.5M-19.2% | $9.3M |
| Operating Income | -$16.9M-0.9% | -$16.8M-2.4% | -$16.4M | N/A | -$15.2M-13.9% | -$13.4M+18.1% | -$16.3M+12.8% | -$18.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$18.1M-23.0% | -$14.7M-4.4% | -$14.1M | N/A | -$28.9M-157.7% | -$11.2M+7.5% | -$12.1M+83.0% | -$71.1M |
| EPS (Diluted) | $-0.69-23.2% | $-0.56+60.3% | $-1.41 | N/A | $-6.31-157.6% | $-2.45 | $-2.65 | N/A |
SNTI Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $52.7M-23.1% | $68.5M-17.2% | $82.8M-15.4% | $97.8M+69.5% | $57.7M-33.6% | $86.9M-14.9% | $102.2M-14.5% | $119.5M |
| Current Assets | $18.2M-44.2% | $32.5M-28.1% | $45.2M-23.3% | $59.0M+239.2% | $17.4M-60.8% | $44.3M-20.3% | $55.7M-21.8% | $71.2M |
| Cash & Equivalents | $12.2M-43.3% | $21.6M-36.2% | $33.8M-30.0% | $48.3M+360.7% | $10.5M-33.9% | $15.9M-33.1% | $23.7M-34.0% | $35.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $44.6M+1.5% | $43.9M-2.3% | $44.9M-37.8% | $72.2M+73.0% | $41.7M-2.4% | $42.8M-7.2% | $46.1M-12.3% | $52.6M |
| Current Liabilities | $12.0M+20.4% | $10.0M-6.9% | $10.7M-18.4% | $13.1M+45.0% | $9.1M0.0% | $9.1M-5.6% | $9.6M-24.2% | $12.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.1M-67.1% | $24.7M-34.9% | $37.9M+47.6% | $25.6M+60.4% | $16.0M-63.8% | $44.1M-21.3% | $56.1M-16.2% | $66.9M |
| Retained Earnings | -$344.1M-5.6% | -$326.0M-4.7% | -$311.2M-4.7% | -$297.1M-0.2% | -$296.5M-10.8% | -$267.7M-4.4% | -$256.5M-5.0% | -$244.3M |
SNTI Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.4M+27.7% | -$13.1M+7.0% | -$14.1M-4.0% | -$13.5M-71.7% | -$7.9M+5.7% | -$8.3M+28.6% | -$11.7M-66.0% | -$7.0M |
| Capital Expenditures | $0-100.0% | $196K | $0-100.0% | $11K | $0 | $0-100.0% | $15K+275.0% | $4K |
| Free Cash Flow | -$9.4M+28.8% | -$13.3M+5.6% | -$14.1M-4.0% | -$13.5M-71.8% | -$7.9M+5.7% | -$8.3M+28.7% | -$11.7M-66.1% | -$7.0M |
| Investing Cash Flow | $0+100.0% | -$184K | $0+100.0% | -$11K-118.3% | $60K | $0+100.0% | -$15K-114.9% | $101K |
| Financing Cash Flow | $124K-87.7% | $1.0M+344.2% | -$414K-100.8% | $51.3M+2002.0% | $2.4M | $0 | $0-100.0% | $556K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SNTI Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -223.2%-163.4pp | -59.8%-22.5pp | -37.3% | N/A | -180.5%-155.1pp | -25.4%-3.8pp | -21.6%+84.6pp | -106.2% |
| Return on Assets | -34.4%-12.9pp | -21.5%-4.4pp | -17.1% | N/A | -50.0%-37.1pp | -12.9%-1.0pp | -11.8%+47.6pp | -59.5% |
| Current Ratio | 1.51-1.7 | 3.26-1.0 | 4.22-0.3 | 4.49+2.6 | 1.92-3.0 | 4.89-0.9 | 5.79+0.2 | 5.62 |
| Debt-to-Equity | 5.49+3.7 | 1.78+0.6 | 1.19-1.6 | 2.81+0.2 | 2.61+1.6 | 0.97+0.1 | 0.82+0.0 | 0.79 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Senti Bioscience's annual revenue?
Senti Bioscience (SNTI) reported $22K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Senti Bioscience profitable?
No, Senti Bioscience (SNTI) reported a net income of -$61.4M in fiscal year 2025, with a net profit margin of -279263.6%.
What is Senti Bioscience's EBITDA?
Senti Bioscience (SNTI) had EBITDA of -$65.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Senti Bioscience's operating margin?
Senti Bioscience (SNTI) had an operating margin of -312631.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Senti Bioscience's net profit margin?
Senti Bioscience (SNTI) had a net profit margin of -279263.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Senti Bioscience's return on equity (ROE)?
Senti Bioscience (SNTI) has a return on equity of -1099.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Senti Bioscience's free cash flow?
Senti Bioscience (SNTI) generated -$43.6M in free cash flow during fiscal year 2025. This represents a -5.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Senti Bioscience's operating cash flow?
Senti Bioscience (SNTI) generated -$43.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Senti Bioscience's total assets?
Senti Bioscience (SNTI) had $51.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Senti Bioscience's capital expenditures?
Senti Bioscience (SNTI) invested $196K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Senti Bioscience spend on research and development?
Senti Bioscience (SNTI) invested $12.9M in research and development during fiscal year 2025.
What is Senti Bioscience's current ratio?
Senti Bioscience (SNTI) had a current ratio of 1.67 as of fiscal year 2025, which is generally considered healthy.
What is Senti Bioscience's debt-to-equity ratio?
Senti Bioscience (SNTI) had a debt-to-equity ratio of 8.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Senti Bioscience's return on assets (ROA)?
Senti Bioscience (SNTI) had a return on assets of -119.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Senti Bioscience's cash runway?
Based on fiscal year 2025 data, Senti Bioscience (SNTI) had $16.4M in cash against an annual operating cash burn of $43.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Senti Bioscience's Piotroski F-Score?
Senti Bioscience (SNTI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Senti Bioscience's earnings high quality?
Senti Bioscience (SNTI) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Senti Bioscience?
Senti Bioscience (SNTI) scores 6 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.